Healthy Volunteers Clinical Trial
Official title:
Sensory Processing and Pain Modulatory Mechanisms Associated With Characteristics of the Infraspinatus Muscle in Individuals With and Without Shoulder Pain
Verified date | September 2023 |
Source | University of Gran Rosario |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The development of chronic pain is a common complication in shoulder pain conditions. Half of these type of patients exhibit persistent pain even after a period of six to twelve months from the start of their pain treatment. Persistent pain is most likely a result of different biological alterations, including but not limited to tissue damage. Another potential cause is neurogenic inflammation, which can be triggered by applying excessive mechanical stress to a structure or region. Neurogenic inflammation can lead to peripheral sensitization and sensitizing the musculoskeletal tissues in the process, and this sensitization will last until the input is removed. Nevertheless, even though peripheral factors are sufficient to perpetuate pain, the role of central mechanisms cannot be excluded as a potential cause of sensitization. Moreover, the evidence is not conclusive about deficiencies in pain modulation processes and presence of central mechanisms in chronic pain conditions. It is well known that chronic shoulder pain presents a multi-factorial nature. Hypersensitivity in this condition has been linked to persistent activation of peripheral nerves, which can result in an increased excitability of the sensory input and reduced inhibitory effect of pain modulatory mechanisms. On the other hand, the role the central sensitization plays is not completely clear in this type of patients, but could also contribute to the hypersensitivity in some patients.However, it has been shown that there is a remarkable variability in the presence of central effects among chronic patients. The aim of this study is to evaluate changes in sensory processing and in pain modulatory mechanisms in individuals with and without shoulder pain.
Status | Completed |
Enrollment | 64 |
Est. completion date | August 8, 2023 |
Est. primary completion date | August 8, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - Volunteers with unilateral shoulder pain and mechanosensitivity in the infraspinatus muscle - pain lasting more than 6 weeks - Healthy volunteers Exclusion Criteria: - Previous surgery/trauma in the upper limb - Previous physiotherapy treatments in the shoulder - Pain intensity = 2 and > 9 (VAS) - History of neurologic disorders - Systemic disorders - Cervical spine injuries or postural deformities - Cortisone injections within the last 6 months - Unusually strenuous activity 48 h before the testing session - Glenohumeral instability - Articular Hyperlaxitude (Beighton > 4) |
Country | Name | City | State |
---|---|---|---|
Argentina | University of Gran Rosario | Rosario | Santa Fe |
Lead Sponsor | Collaborator |
---|---|
University of Gran Rosario |
Argentina,
Mista CA, Laugero SJ, Adur JF, Andersen OK, Biurrun Manresa JA. A new experimental model of muscle pain in humans based on short-wave diathermy. Eur J Pain. 2019 Oct;23(9):1733-1742. doi: 10.1002/ejp.1449. Epub 2019 Jul 24. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Conditioned pain modulation (CPM) | CPM will be assessed by immersing the hand up to the wrist in a cold water bath (0.6-0.8°) with a circulating water pump. The dominant arm for healthy and the symptomatic side for unilateral shoulder pain volunteers will be immerse in the cold-water bath. In general, the conditioning stimulus will be applied for 2 min or maximum tolerance (whichever comes first). A computerized, custom-made visual analog scale (VAS) will be used to continuously track the response profile to conditional stimuli across participants during the application of CPM. A numeric rating scale ranging from 0 to 100, where 0 represents no perception, 30 represents pain threshold (defined as the time to reach a painful sensation at the predefined stimulation intensity) and 100 represents the tolerance threshold (defined as the sensation of pain when becomes intolerable). Before and immediately after the immersion, PPT measurements will be assessed on both infraspinatus muscles. | At baseline and immediately after the cold-water immersion in the first session. | |
Primary | Pressure pain threshold (PPT) | Change in the PPT (kPa) will be assessed bilaterally over the medial portion of the infraspinatus muscle using a digital algometer (Somedic SenseLab AB, Sweden) with a 1-cm2 round tip. Pressure will be gradually increased from 0 kPa at a rate of approximately 50 kPa/s (maximal achievable pressure: 2,000 kPa). The volunteers will be asked to press the button when they perceive that the pressure changes to pain, stopping the estimation at this point. The assessment will be repeated 3 times for each sides, alternating sides between measurements. Each measure will be performed at 30-second intervals. | At baseline and 30 - 60 minutes after the short-wave diathermia in the second session. | |
Secondary | Thermal sensitivity thresholds | Changes in cold and heat perception thresholds (CDT and HDT, respectively, in ºC), and heat pain thresholds (HPT). The cold/heat stimuli will be applies over the infraspinatus muscle area on both participant's shoulder. Tests will be performed in randomized order. Stimuli will be delivered using a thermode with an 9 cm2 contact. The baseline temperature will be set at 30°C and the skin will be cooled (CDT) or heated (HDT) at a rate of 1°C/sec until participants report the first sensation of cold/heat and the pain sensation for the HPT (minimum temperature 0 °C; maximum temperature 50 °C). The thermode then will return to 30 °C at a rate of 5°/sec. A 30-s rest interval will be taken before the next measure. Each test will be repeated 3 times at each assessment point (30 s inter-stimulus interval). | At baseline in the first session. | |
Secondary | Pain intensity | The Visual Analogue Scale (VAS) will be use to assess pain intensity. This scale consists of a sequence of numbers from 0 to 10, in which 0 represents "no pain" and 10 represents "worst pain imaginable". | At baseline in the first session. | |
Secondary | Shoulder joint position sensation | Assessment of shoulder joint position sense (º) in the dominant shoulder for healthy and unilateral shoulder pain volunteers in a supine blindfolded position. The physiotherapist will externally rotate the arm to a position of 75% of maximum external rotation, referred to as the target angle, and participants will be instructed to hold that position for three seconds before the physiotherapist passively returns the arm to the starting position. The participant will then be instructed to actively rotate the arm back to the target angle. The physical therapist will measure the angle with a digital inclinometer and record the difference from the target angle (joint position perception error). The measurement will be repeated three times and the mean value of the joint position perception error is used for analysis. | At baseline in the first session. | |
Secondary | Myoelectrical activity (EMG) | Change in muscle activity will be assessed. Monopolar multichannel recording (6 channels) will be distributed spatially across the infraspinatus muscle, and monopolar channels will be recorded for the medial and posterior deltoid muscle. BIO AMP Biopotential amplifier will be used for recording the EMG signals, 8-channel (2 KHz) (UNER, Argentina) during execution of the motor tasks. EMG will be recorded before and after SWD application to assess redistribution of the muscle activity induced by the transient pain. For the unilateral shoulder pain volunteers, EMG will be recorded only during the motor tasks. | At 10 minutes before and 30 - 60 minutes after the application of SWD for control in the second session. | |
Secondary | Pain distribution | Extension of the reported pain drawings. The results will be expressed as the percentage of the total body area. | At 15 - 30 minutes before recording of muscle activity for chronic patients and 30 - 60 minutes after the application of SWD for control in the second session. | |
Secondary | American Shoulder and Elbow Surgeons score (ASES) | Assesment of American Shoulder and Elbow Surgeons score scale will be used to assess the extent of symptoms in the involved shoulder, and as additional scores to classify the participants into both groups.
This composite instrument provides results in the 0 to 100 range, where 0 indicates a worse shoulder condition and 100 indicates best shoulder condition, so the greater the score, the lower the level of shoulder disability. |
At baseline in the first session. | |
Secondary | Örebro Musculoskeletal Pain Questionnaire (ÖMPQ) | Assesment of Örebro Musculoskeletal Pain Questionnaire will be used to assesses the psychosocial factors in people with complaints of musculoskeletal disorders and predict those likely to develop persistent symptoms. The total score will range between 1 and 100, with a score 1 indicating no risk estimated for future work disability, and with a score 100 is the worst score. | At baseline in the first session. | |
Secondary | Modified Likert scale | A modified self-report Likert scale was used to follow the temporal progression of muscle pain/soreness after SWD, with 0 defining a complete absence of soreness and 6 indicating severe soreness. | At 15 - 30 minutes before recording of muscle activity for chronic patients and 30 - 60 minutes after the application of SWD for control in the second session. | |
Secondary | McGill questionnaires | McGill questionnaires will be used to describe the sensation. | At 15 - 30 minutes before recording of muscle activity for chronic patients and 30 - 60 minutes after the application of SWD for control in the second session. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |